康莱特注射液辅助治疗在晚期非小细胞肺癌患者中的效果研究
|
摘要
目的观察康莱特注射液辅助治疗晚期非小细胞肺癌(NSCLC)化疗患者的效果。方法选择收治的晚期NSCLC化疗患者64例为研究对象,依据患者是否同意使用康莱特注射液辅助化疗分为KLT组(在TP方案上加用康莱特注射液辅助化疗)和常规组(仅接受TP方案进行常规化疗),每组32例,比较两组患者的客观疗效、肿瘤标记物、基质金属蛋白酶相关因子及不良反应的差异。结果 KLT组客观疗效总有效率明显高于常规组(P<0.05);干预后,两组癌胚抗原(CEA)、糖类抗原125(CA125)、神经烯醇化酶(NSE)水平均明显下降(P<0.05),且KLT组CEA、CA125、NSE水平均低于常规组(P<0.05);干预后,两组基质金属蛋白酶(MMP)-9、MMP-2、MMP-9、基质金属蛋白酶抑制剂(TIMP)-1、TIMP-2水平均明显降低(P<0.05),且KLT组MMP-2、MMP-9、TIMP-1、TIMP-2水平均低于常规组(P<0.05);KLT组的不良反应总发生率(50.00%)明显低于常规组(75.00%),差异有统计学意义(P<0.05)。结论康莱特辅助化疗可降低肿瘤标记物和基质金属蛋白酶相关指标,疗效明显,不良反应少。
Objective To observe the influence of Kanglaite(KLT)injection adjuvant therapy on the effect in the patients with advanced non-small cell lung cancer(NSCLC).Methods Sixty-four cases of NSCLC chemotherapy treated in the hospital were selected as the study subjects and divided into the KLT group(n=32,adding KLT adjuvant chemotherapy based on TP regimen)and routine group(n=32,only receiving the TP regimen for conducting the routine chemotherapy)according to whether the patients agreed to use KLT injection adjuvant chemotherapy.The objective efficacy,tumor markers,matrix metalloproteinase-related factors and adverse reactions were compared between the two groups.Results The total effective rate of objective efficacy in the KLT group was significantly higher than that in the routine group(P<0.05).After intervention,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and neuronolase(NSE)in the two groups were significantly decreased(P<0.05),moreover the levels of the above tumor markers in the KLT group were lower than those in the routine group(P<0.05).After intervention,the levels of matrix metalloproteinase(MMP)-2,MMP-9,TIMP-1 and TIMP-2 in the two groups significantly decreased(P<0.05),moreover the levels of the above indicators in KLT group were lower than those in routine group(P<0.05).The total incidence rate of adverse reactions in the KLT group was significantly lower than that in the routine group(50.00%vs.75.00%,P<0.05).Conclusion The KLT adjuvant chemotherapy can reduce the levels of tumor markers and matrix metalloproteinase-related indicators with obvious efficacy and few adverse reactions.
Objective To observe the influence of Kanglaite(KLT)injection adjuvant therapy on the effect in the patients with advanced non-small cell lung cancer(NSCLC).Methods Sixty-four cases of NSCLC chemotherapy treated in the hospital were selected as the study subjects and divided into the KLT group(n=32,adding KLT adjuvant chemotherapy based on TP regimen)and routine group(n=32,only receiving the TP regimen for conducting the routine chemotherapy)according to whether the patients agreed to use KLT injection adjuvant chemotherapy.The objective efficacy,tumor markers,matrix metalloproteinase-related factors and adverse reactions were compared between the two groups.Results The total effective rate of objective efficacy in the KLT group was significantly higher than that in the routine group(P<0.05).After intervention,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and neuronolase(NSE)in the two groups were significantly decreased(P<0.05),moreover the levels of the above tumor markers in the KLT group were lower than those in the routine group(P<0.05).After intervention,the levels of matrix metalloproteinase(MMP)-2,MMP-9,TIMP-1 and TIMP-2 in the two groups significantly decreased(P<0.05),moreover the levels of the above indicators in KLT group were lower than those in routine group(P<0.05).The total incidence rate of adverse reactions in the KLT group was significantly lower than that in the routine group(50.00%vs.75.00%,P<0.05).Conclusion The KLT adjuvant chemotherapy can reduce the levels of tumor markers and matrix metalloproteinase-related indicators with obvious efficacy and few adverse reactions.
引文
[1]陈闽江,王孟昭.非小细胞肺癌免疫治疗进展[J].国际呼吸杂志,2016,36(18):34-41.
[2]麻宏亮,张洪涛.化疗联合中药对中晚期非小细胞肺癌患者免疫功能和KPS评分的影响[J].海南医学,2014,25(15):2271-2272.
[3]徐晓卫,林观样,袁拯忠,等.康莱特联合化疗治疗非小细胞肺癌的系统评价[J].中华中医药学刊,2014,32(4):733-739.
[4]吴锡林.香菇多糖联合化疗应用于晚期肺癌治疗的临床分析[J].中华中医药学刊,2015,32(2):456-458.
[5]李艳,郭其森.晚期非小细胞肺癌维持治疗进展[J].中华肿瘤防治杂志,2014,21(10):800-804.
[6]胡毅,陶海涛.晚期非小细胞肺癌的药物治疗进展[J].中国药物应用与监测,2014,11(6):329-333.
[7]邓新娜,赵淑芳,赵海静,等.康莱特注射液对晚期非小细胞肺癌化疗患者免疫功能的影响[J].现代中西医结合杂志,2014,23(34):3767-3769.
[8]张海英.康莱特注射液对非小细胞肺癌的辅助治疗效果分析[J].现代中西医结合杂志,2014,23(9):997-999.
[9]彭东旭,方晓娟,杜均详,等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].临床肺科杂志,2016,21(7):1306-1309.
[10]杨勐航,臧远胜,李兵.肺癌新生血管生成机制研究进展[J].第二军医大学学报,2013,34(4):434-439.
[11]张慧丰,左萍萍.肺癌转移机制研究进展[J].医学研究杂志,2013,42(10):4-6.
[2]麻宏亮,张洪涛.化疗联合中药对中晚期非小细胞肺癌患者免疫功能和KPS评分的影响[J].海南医学,2014,25(15):2271-2272.
[3]徐晓卫,林观样,袁拯忠,等.康莱特联合化疗治疗非小细胞肺癌的系统评价[J].中华中医药学刊,2014,32(4):733-739.
[4]吴锡林.香菇多糖联合化疗应用于晚期肺癌治疗的临床分析[J].中华中医药学刊,2015,32(2):456-458.
[5]李艳,郭其森.晚期非小细胞肺癌维持治疗进展[J].中华肿瘤防治杂志,2014,21(10):800-804.
[6]胡毅,陶海涛.晚期非小细胞肺癌的药物治疗进展[J].中国药物应用与监测,2014,11(6):329-333.
[7]邓新娜,赵淑芳,赵海静,等.康莱特注射液对晚期非小细胞肺癌化疗患者免疫功能的影响[J].现代中西医结合杂志,2014,23(34):3767-3769.
[8]张海英.康莱特注射液对非小细胞肺癌的辅助治疗效果分析[J].现代中西医结合杂志,2014,23(9):997-999.
[9]彭东旭,方晓娟,杜均详,等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].临床肺科杂志,2016,21(7):1306-1309.
[10]杨勐航,臧远胜,李兵.肺癌新生血管生成机制研究进展[J].第二军医大学学报,2013,34(4):434-439.
[11]张慧丰,左萍萍.肺癌转移机制研究进展[J].医学研究杂志,2013,42(10):4-6.